Table 2.
Incident rates of coronary artery disease, stroke, and heart failure between urate-lowering drug users vs. non-users after propensity matching.
| Outcome | Urate-lowering therapy | cHR (95%CI) | P | aHR (95%CI) | P | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| No | Yes | |||||||||
| Event | PY | IR | Event | PY | IR | |||||
| CAD | 155 | 8,882 | 1.7 | 123 | 9,506 | 1.3 | 0.73 (0.58, 0.93) | 0.01 | 0.7 (0.55, 0.89) | 0.004 |
| Stroke | 100 | 9,137 | 1.1 | 78 | 9,657 | 0.8 | 0.73 (0.55, 0.99) | 0.04 | 0.68 (0.5, 0.92) | 0.01 |
| Ischemic stroke | 54 | 9,137 | 0.6 | 35 | 9,657 | 0.4 | 0.61 (0.4, 0.93) | 0.02 | 0.59 (0.38, 0.91) | 0.02 |
| Hemorrhagic stroke | 14 | 9,137 | 0.2 | 9 | 9,657 | 0.1 | 0.6 (0.26, 1.4) | 0.24 | 0.52 (0.22, 1.23) | 0.14 |
| Heart failure | 39 | 9,364 | 0.4 | 39 | 9,792 | 0.4 | 0.95 (0.61, 1.48) | 0.81 | 0.92 (0.58, 1.45) | 0.72 |
IR, incidence rate, per 100 person-years; CI, confidence interval; P, P-value; cHR, crude hazard ratio; aHR, adjusted hazard ratio, controlling for sex, age, area, every comorbidity, and drug in Table 1; CAD, coronary artery disease.